Figure 1 Inc. has raised $5 million to support the global expansion of its app, which has been called medicine’s answer toInstagram, Lora Kolodny reports for Dow Jones VentureWire. With Figure 1’s HIPAA-compliant app, health-care professionals can share high-quality medical images within their fields of specialty–such as patient photos, brain scans or X-rays–for teaching purposes and to attain feedback from each other about possible diagnoses and treatments. Union Square Ventures, an earlier investor in Figure 1, led the new round, joined by other existing investors including Rho Canada, Version One Ventures and Graph Ventures, as well as Allen & Co. and individual investors.
ALSO IN TODAY’S VENTUREWIRE (subscription required):
Kleiner Perkins Caufield & Byers has added another general partner, Eric Feng, to its investing team as part of a push to bring new blood into the 43-year-old venture firm. The move is a return to Kleiner Perkins for Mr. Feng, who was most recently the chief technology officer for the news aggregator Flipboard Inc., a Kleiner Perkins portfolio company. Mr. Feng was also a partner at Kleiner Perkins in 2010, when he served as technical adviser to former Vice President Al Gore and invested in green tech companies.
Lyra Health Inc., which aims to help people find treatment for mental-health problems, said it had raised $35 million from investors led by Greylock Partners and existing investor Venrock. Other investors in the Series A round included Breyer Capital,Providence Health & Services, Origin Capital Management and Castlight HealthInc.CSLT -0.21%, which helps large companies like Wal-Mart Stores Inc.WMT -7.78%and Alphabet Inc.GOOGL +0.22% manage health-care costs.
CyPhy Works Inc. has raised $22 million in Series B venture funding to ramp up manufacturing and ship new models, including untethered drones for the consumer market. Bessemer Venture Partners led the investment in CyPhy and was joined by strategic investors Motorola Solutions Venture MSI -0.00% Capital, the UPS Strategic Enterprise Fund and Draper Nexus, as well as CyPhy’s earlier backers Lux Capital and General Catalyst Partners.
Audentes Therapeutics Inc., a gene-therapy company, has raised a $65 million Series C round to move its three treatments further into clinical development and to set up manufacturing capabilities. The funding was co-led by existing investor Sofinnova Ventures and new investor Redmile Group. The round was joined by new investors RA Capital Management, T. Rowe Price Associates TROW +0.90%, Rock Springs Capital, Cormorant Asset Management, Cowen Private Investments and Foresite Capital.